Prodia the CRO Receives Frost & Sullivan 2026 Customer Value Recognition
SAN ANTONIO — September 8, 2026 PT Prodia Diacro Laboratories (Prodia the CRO) has received Frost & Sullivan’s 2026...
GCP
Advertisement
Fortrea to Acquire Worldwide Clinical Trials’ Early Phase Unit
DURHAM, N.C. and RESEARCH TRIANGLE PARK, N.C., September 2, 2026 Fortrea has entered into a definitive agreement to acquire...
Cellenkos Secures FDA IND Clearance for CK0802 in GVHD Trial
HOUSTON, TEXAS, May 04, 2026 Cellenkos has announced that the U.S. Food and Drug Administration (FDA) has granted Investigational...
UCB to Acquire Candid Therapeutics in $2.2B Immunology Deal
SAN DIEGO, CALIFORNIA, May 03, 2026 UCB has announced a definitive agreement to acquire Candid Therapeutics in a transaction...
Ascidian Therapeutics Advances ACDN-01 in Stargardt Trial
BOSTON, MASSACHUSETTS, May 04, 2026 Ascidian Therapeutics has announced the completion of the adult dose escalation phase in its...
Advertisements
Insmed Unveils Phase 3 ARIKAYCE Data at ATS 2026
BRIDGEWATER, NEW JERSEY, May 04, 2026 Insmed Incorporated has announced the presentation of multiple clinical and real-world data sets...
Atossa Gains FDA RPD Status for Z-Endoxifen in MAS
SEATTLE, WASHINGTON, May 04, 2026 Atossa Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted...
Celcuity Reports Phase 3 Success for Gedatolisib in Breast Cancer
MINNEAPOLIS, MINNESOTA, May 01, 2026 Celcuity has announced positive topline results from its Phase 3 VIKTORIA-1 trial, demonstrating a...
BioCryst, Neopharmed Sign $345M Europe HAE Deal
RESEARCH TRIANGLE PARK, NORTH CAROLINA, May 04, 2026 BioCryst Pharmaceuticals has announced a strategic European licensing agreement with an...
Bambusa Therapeutics Completes BBT001 Trial Enrollment
BOSTON, MASSACHUSETTS, April 30, 2026 Bambusa Therapeutics has announced the successful completion of patient enrollment in its Phase 1b/2a...
Advertisement
